A recently proposed "ethynylogation" pharmacomodulation approach, first envisaged in the series of anticancer lipidic dialkynylcarbinols (DACs) H-C≡C-CH(OH)-C≡C-R at the levels of the H-C⋮ and ⋮C-R bonds for R = n-C 12 H 25 , is completed here at the level of the (HO)C-H bond. The sodevised mono-lipidic trialkynylcarbinol (TAC) target (HC≡C) 2 C(OH)-C≡CR and its bis-lipidic counterpart HC≡C-C(OH)(C≡CR) 2 were synthesized in 4 steps with 33 % and 23 % overall yield, respectively. Their antitumor cytotoxicity has been evaluated towards HCT116 cells: while the latter doubly lipidic TAC is totally inactive (IC 50 > 120 µM), the former DAC-ethynylogous TAC still exhibits a significant toxicity with an IC 50 of 40 µM.
Introduction
With the view to setting the title terms in a proper context, scholar emphasis is first given to the basic notion of structure-activity relationships (SARs), which correlate the presence of a generic chemical unit with particular biological/therapeutic effects [1] . The first-key SAR unit can be a global molecular skeleton that can be modified/ decorated by various second-key functional units (e.g.
norsteroids, corticosteroids or macrolides, related to contraceptive, anti-inflammatory or antibiotic effects, respectively). On the other hand, the first-key SAR unit can be restricted to a local well-defined substructure, called a pharmacophore [2] , that can be embedded in various second-key environments (e.g. betalactams, benzodiazepines or arylpropionic acids related to antimicrobial, anxiolytic or analgesic effects, respectively). It is worth noting that SARs can be more or less specific: the number of identified antitumor pharmacophores is thus actually as large as the number of targetable biochemical pathways, and almost as large as the number of marketed anticancer drugs [3] .
Classical optimization approaches around a given pharmacophore consist in sequential modifications of the local environment by isomerization (e.g. enantiomerization), reduction/oxidation (e.g. CH-OH → C=O),
analogation (e. g. O→S, CH→N), C-H fluorination or general C-H substitution.
Homologation (by CH 2 -insertion) and vinylogation (by -HC=CH-insertion) are also established pharmacomodulation approaches, within the pharmacophoric unit itself [4] or at its periphery. An alternative "ethynylogation" approach has been recently proposed [5, 6] : it is based on the assumption that a third-key SAR criterion would be a distance constraint between the pharmacophore and any component of its surrounding, independently from any relative spatial orientation constraint between them (so regardless conformational effects).
The ethynylogation approach has been first implemented in the series of synthetic lipidic dialkynylcarbinols (DACs) of general formula
HC≡C-CH(OH)-C≡CR, inspired from natural lipidic alkenyl-alkynylcarbinols (AACs) (E)-HC≡C-CH(OH)-CH=CHR extracted from
marine sponges [7] . Beyond efforts aiming at the total synthesis of natural AACs [8], synthesis and biological evaluation of both simplified and modified congeners thereof allowed the identification of non-natural DACs as potent in vitro antitumor cytotoxic agents, in particular against the HCT116 cell-line [9] . Starting from the recently disclosed lead 1 (R = n-C 12 H 25 , IC 50 ≈ 0.10 µM; Figure 1 ) [5,9a] , the C 5 OH DAC unit itself, C≡C-C(OH)-C≡C, has been formally separated from either two components of its surrounding, the terminal acetylenic H and the lipidic chain R, by a distance of ca 2.4 ± 0.1 Å through the insertion of a C 2 ethyndiyl unit. The corresponding independent ethynylogations thus defined the external and internal butadiynyl-alkynylcarbinols (BACs) 2 and 3, respectively, which were synthesized in either racemic or 90 % ee-scalemic forms [5] . Compared to 1, while the external BAC 2 was found to display a decreased cytotoxicity (IC 50 ≈ 10 µM for rac-2), diynes" [11] or triynes were obtained as solid products and characterized by 1 H, 13 C NMR spectroscopy and DCI/CH 4 HRMS.
Scheme 2. Four-step synthesis of the bis-lipidic TAC 8.
The cytotoxicity of the TACs 4 and 8 was evaluated towards the HCT116 cell-line (Table 1) , and compared with that of the parent independently from angular parameters and local steric hindrance) entails a "proportional" variation of the biological activity at stake [12] .
Conclusions and perspectives
With the view to testing further possible merits of the formal ethynylogation approach, the present results complete the scope of SARs between DACs and anticancer cytotoxicity:
beyond the formerly explored BAC series [5] , 
Experimental part

Synthesis material and methods
The reactions were carried out under an argon atmosphere, in solvents previously dried and distilled: tetrahydrofuran (THF) over sodium/ benzophenone, dichloromethane (DCM) over 3-ethynylheptadeca-1,4-diyn-3-ol (4) . To a solution of the silylated TAC 7 (109 mg, 0.261 mmol, 1equiv.) in methanol (4 mL) was added 95, 29.70, 29.67, 29.66, 29.55, 29.39, 29.16, 28.92, 28.41, 22.72, 18.75 (2 CH 3 ) 94, 29.67, 29.65, 29.62, 29.46, 29.38, 29.05, 28.90, 27.58, 22.72, 19.13, (2CH 3 ) 14.14; IR (neat):  (cm 2965 , 2158 , 1622 , 1255 , 1249 , 1163 MS (DCI-CH 4 95, 29.71, 29.68, 29.65, 29.54, 29.39, 29.13, 28.90, 28.12, 22.72, 18.71, (2 CH 3 ) .
